Open AccessRosiglitazone Monotherapy in Mild-to-Moderate Alzheimer’s Disease: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Study
Author(s) -
Michael Gold,
Claire Alderton,
Marina Zvartau-Hind,
Sally Egginton,
Ann M. Saunders,
Michael C. Irizarry,
Suzanne Craft,
Gary E. Landreth,
Ülla Linnamägi,
Sharon Sawchak
Publication year - 2010
Publication title -
dementia and geriatric cognitive disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.026
H-Index - 110
eISSN - 1421-9824
pISSN - 1420-8008
DOI - 10.1159/000318845
Subject(s) - placebo , medicine , tolerability , apolipoprotein e , alzheimer's disease , gastroenterology , endocrinology , psychology , adverse effect , disease , pathology , alternative medicine
A phase II study of the peroxisome proliferator-activated receptor-γ agonist rosiglitazone extended release (RSG XR) in mild-to-moderate Alzheimer's disease (AD) detected a treatment benefit to cognition in apolipoprotein E(APOE)-ε4-negative subjects. The current phase III study with prospective stratification by APOE genotype was conducted to confirm the efficacy and safety of RSG XR in mild-to-moderate AD. An open-label extension study assessed the long-term safety and tolerability of 8 mg RSG XR.